Search results for "Diseases of the nervous system"

showing 3 items of 233 documents

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multi…

2018

BACKGROUND: The aim of the study was to evaluate the achievement of 'no evidence of disease activity' (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. METHODS: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs. RESULTS: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS tre…

safetymedicine.medical_specialtydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide; pharmacology; neurology; neurology (clinical)Populationefficacylcsh:RC346-429Disease activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineTeriflunomideteriflunomideMedicine030212 general & internal medicineno evidence of disease activity 3educationlcsh:Neurology. Diseases of the nervous systemOriginal ResearchPharmacologyeducation.field_of_studydimethyl fumarateDimethyl fumaratebusiness.industryMultiple sclerosismedicine.diseasechemistryRelapsing remittingNeurologySettore MED/26 - NeurologiaReal wordNeurology (clinical)business030217 neurology & neurosurgerydimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide
researchProduct

Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients Treated With Continuous Positive Airway Pressure: Data From the European Sleep Apnea…

2021

Excessive daytime sleepiness (EDS) is a symptom of obstructive sleep apnea (OSA) that resolves under treatment with continuous positive airway pressure (CPAP). In some patients, sleepiness persists despite CPAP treatment. We retrospectively analyzed data on subjective residual EDS, assessed as an Epworth Sleepiness Scale score (ESS) >10, in patients from the European Sleep Apnea Database (n = 4,853, mean age +/- SD 54.8 +/- 11.8 years, 26.1% females), at baseline and at the first visit (median follow-up: 5 months, interquartile range 3-13). An ESS > 10 occurred in 56% of patients at baseline and in 28.2% of patients at follow-up. Residual EDS was analyzed in 2,190 patients (age: 55.1 +/- 12…

sleep latencyResidual Sleepinessmedicine.medical_treatment[SDV]Life Sciences [q-bio]Excessive daytime sleepinessSettore MED/10 - Malattie Dell'Apparato Respiratoriocomputer.software_genreCpap adherence03 medical and health sciences0302 clinical medicineInterquartile rangeCpap Usemedicinefollow-upContinuous positive airway pressureObesityRC346-429ComputingMilieux_MISCELLANEOUSresidual sleepnessOriginal ResearchWake-Active NeuronsDatabasebusiness.industryresidual sleepineEpworth Sleepiness ScaleSleep apneaEpworth sleepness ScaleEpworth Sleepiness Scalemedicine.diseaseCPAP adherenceImportant Differencenervous system diseasesrespiratory tract diseasesScaleObstructive sleep apneaLifestyle factors030228 respiratory systemNeurologysleep durationHuman medicineNeurology. Diseases of the nervous systemNeurology (clinical)medicine.symptombusinesscomputer030217 neurology & neurosurgery
researchProduct

Recovery of mobility function and life-space mobility after ischemic stroke: the MOBITEC-Stroke study protocol

2020

Abstract Background Stroke is a major cause of disability and stroke incidence increases with age. Stroke frequently results in permanent limitations of mobility, and, consequently, the need for the help of others in activities of daily living. In order to optimize rehabilitative efforts and their functional outcomes, detailed knowledge of the functional recovery process, regarding mobility, is needed. Objectives of the MOBITEC-Stroke study are: 1.) To characterize mobility, including lower extremity physical function (LEPF) and life space (the geospatial extent of all of a person’s movements), and changes in mobility within the first year after stroke. 2.) To identify and characterize subg…

walking speed.Quality of lifeAgingaccelerometersGPSClinical Neurologyfyysinen toimintakykyspatial behaviourelämänlaatuWalking speedtoipuminenlcsh:RC346-429aivohalvausmobility limitationStudy ProtocolActivities of Daily Livingcohort studyliikuntakykyQuantitative gait analysisHumans910 Geography & travelquantitative gait analysislcsh:Neurology. Diseases of the nervous systemaskelmittaritRetrospective StudiesagingStroke RehabilitationGeneral MedicineRecovery of FunctionSpatial behaviourMobility limitationkävely10122 Institute of Geography2728 Neurology (clinical)quality of lifepaikkatietojärjestelmätAccelerometersCohort studyikääntyneetBMC Neurology
researchProduct